论文信息 - The cat-and-mouse game of BTK inhibition. - 字舞流文

The cat-and-mouse game of BTK inhibition.

H. Wendel | Ana Portelinha

[1] A. Wiestner,et al. -----NRX-0492 Degrades Wildtype and C481 Mutant BTK and Demonstrates in vivo Activity in CLL Patient Derived Xenografts. , 2022, Blood.

[2] O. Abdel-Wahab,et al. Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. , 2022, The New England journal of medicine.

[3] G. Acton,et al. Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies , 2021, Haematologica.

[4] Dahlia R. Weiss,et al. Nx-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies , 2020 .

[5] G. Packham,et al. Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors , 2020, Exploration of targeted anti-tumor therapy.

[6] Michael R. Green,et al. Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity. , 2019, JCI insight.

[7] J. Byrd,et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. , 2014, The New England journal of medicine.

[8] Juthamas Sukbuntherng,et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.